## Data Sharing Statement

| Item | Question | Authors’ Response (place “-” if not applicable) |
|------|----------|-------------------------------------------------|
| 1    | Would you like to share data collected for your study to others? | Yes |
| 2    | If not, would you like to share the reason for your decision? | - |
| 3    | What data in particular will be shared? | The therapeutic outcomes data in particular will be shared. This study demonstrated that atenolol was effective in the treatment of IHs. Compared to propranolol, atenolol seems to have a similar effect on IHs. Furthermore, atenolol seems to be less frequently associated with potentially life-threatening side effects. |
| 4    | Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested. |
| 5    | When will data availability begin? | From the publication date. |
| 6    | When will data availability end? | Four years within the publication date, since randomized controlled clinical trial will be conducted to prove the equal efficacy and better tolerance of atenolol compared with propranolol. |
| 7    | To whom will you share the data? | Oral and maxillofacial surgeons and pediatricians who are interested in studies of infantile hemangioma. |
| 8    | For what type of analysis or purpose? | For analysis to evaluate the safety of oral atenolol in infantile hemangioma patients. |
| 9    | How or where can the data/documents be obtained? | Emails could be sent to the address below to obtain the shared data: davidzhengjw@hotmail.com. |

**Article Info**

http://dx.doi.org/10.21037/atm-20-5359
| 10 | Any other restrictions? | We may balance the potential benefits and risks for each request and then provide the data that could be shared. |